Wolf Administration Announces Biopharmaceutical Company Adaptimmune Therapeutics to Create 110 New Jobs in Philadelphia

October 09, 2015

Philadelphia, PA – Governor Tom Wolf announced today that Adaptimmune Therapeutics, a clinical stage biopharmaceutical company focused on developing T-cell receptor cancer immunotherapy treatments, will create at least 110 new, high-paying jobs with a new expansion project.

“Adaptimmune has shown a true commitment to Pennsylvania, and today’s announcement is great news for the commonwealth as 110 new, high-paying jobs will be created with this project,” said Governor Tom Wolf. “My budget proposal includes sustained funding for the life science sector and increased support for research within the industry so that we continue to see successes like this for years to come.”

Adaptimmune Therapeutics will expand operations and will relocate to a 46,000-square-foot site at the Philadelphia Navy Yard. The company plans to invest more than $4 million at the site, and has also committed to create at least 110 new, full-time jobs and to retain its 14 existing positions over the next three years.

The company received a funding proposal from the Department of Community and Economic Development including a Pennsylvania First Program grant for $150,000.

“This new facility will allow Adaptimmune to more than triple the number of its employees in Pennsylvania with well-paying positions that will contribute to the overall economic growth in the city and region,” said James Noble, Chief Executive Officer at Adaptimmune. “We see our commitment to the Navy Yard as a vote of confidence in Pennsylvania as a powerhouse for scientific and medical achievement and we thank Governor Wolf for his outstanding commitment to making the state a great place to create new businesses and jobs. We look forward to a long and successful partnership with the Navy Yard, Philadelphia and Pennsylvania in the years to come.”

The project was coordinated by the Governor’s Action Team, an experienced group of economic development professionals who report directly to the Governor and work with businesses that are considering locating or expanding in Pennsylvania, the City of Philadelphia, and the Philadelphia Industrial Development Corporation.

“Adaptimmune Therapeutics’ decision to expand in our city is further evidence that Philadelphia is the number one place to be in the United States for innovative, exciting healthcare companies,” said Mayor Nutter. “With our leading healthcare institutions, world-class universities, and talented workforce, Philadelphia is on the forefront of innovation and discovery in the life sciences. We couldn’t be more excited that Adaptimmune is beginning this next phase of its growth in Philadelphia.”

Founded in 2008, Adaptimmune is a clinical stage biopharmaceutical company focused on novel cancer immunotherapy products based on its T-cell receptor platform. The company aims to utilize the body’s own machinery – the T-cell – to target and destroy cancer cells by using engineered, increased affinity T-cell receptors (TCRs) as a means of strengthening natural patient T-cell responses.

For further information on Adaptimmune Therapeutics, visit www.adaptimmune.com

For more information about the Governor’s Action Team, visit www.newpa.com.

SHARE Email Facebook Twitter